[HTML][HTML] Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis

IL Alberts, SE Seide, C Mingels, KP Bohn, K Shi… - European journal of …, 2021 - Springer
Purpose Many radiotracers are currently available for the detection of recurrent prostate
cancer (rPC), yet many have not been compared head-to-head in comparative imaging …

[HTML][HTML] The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta …

R Wang, G Shen, M Huang, R Tian - Frontiers in Oncology, 2021 - frontiersin.org
Background Diagnosing the biochemical recurrence (BCR) of prostate cancer (PCa) is a
clinical challenge, and early detection of BCR can help patients receive optimal treatment …

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

MJ Morris, SP Rowe, MA Gorin, L Saperstein… - Clinical Cancer …, 2021 - AACR
Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …

3-Year freedom from progression after 68Ga-PSMA PET/CT–triaged management in men with biochemical recurrence after radical prostatectomy: results of a …

L Emmett, R Tang, R Nandurkar, G Hruby… - Journal of Nuclear …, 2020 - Soc Nuclear Med
68Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in
men with biochemical recurrence (BCR) after radical prostatectomy (RP), but its longer-term …

Using PSMA imaging for prognostication in localized and advanced prostate cancer

MJ Roberts, T Maurer, M Perera, M Eiber… - Nature Reviews …, 2023 - nature.com
The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

[HTML][HTML] Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga …

DA Ferraro, JH Rüschoff, UJ Muehlematter… - Theranostics, 2020 - ncbi.nlm.nih.gov
Prostate-specific membrane antigen (PSMA) targeted PET has a high detection rate for
biochemical recurrence (BCR) of prostate cancer (PCa). Nevertheless, even at high prostate …

[HTML][HTML] Imaging for metastasis in prostate cancer: a review of the literature

A Turpin, E Girard, C Baillet, D Pasquier… - Frontiers in …, 2020 - frontiersin.org
Background: Initial staging and assessment of treatment activity in metastatic prostate
cancer (PCa) patients is controversial. Indications for the various available imaging …

Salvage therapy for prostate cancer after radical prostatectomy

NG Zaorsky, J Calais, S Fanti, D Tilki, T Dorff… - Nature Reviews …, 2021 - nature.com
More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a
biochemical recurrence after radical prostatectomy. Clinical guidelines for the management …

Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross‐sectional study of the additive diagnostic value of gallium‐68 prostate‐specific membrane …

A Amin, A Blazevski, J Thompson… - BJU …, 2020 - Wiley Online Library
Objectives Primary objectives: To determine the additive value of gallium‐68 prostate‐
specific membrane antigen (PSMA) positron emission topography (PET)/computed …

Prostatectomy bed image-guided dose-escalated salvage radiotherapy (SPIDER): an international multicenter retrospective study

N Benziane-Ouaritini, T Zilli, A Giraud… - European Urology …, 2023 - Elsevier
Background Management of macroscopic local recurrence (MLR) after radical prostatectomy
is a challenging situation with no standardized approach. Objective The objective of our …